Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

6,123JPY
19 Jun 2019
Change (% chg)

-- (--)
Prev Close
¥6,123
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,143,342
52-wk High
¥6,238
52-wk Low
¥3,277

Latest Key Developments (Source: Significant Developments)

EMA Validates Daiichi Sankyo's Marketing Authorization Application For Pexidartinib
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::EMA VALIDATES DAIICHI SANKYO'S MARKETING AUTHORIZATION APPLICATION FOR PEXIDARTINIB FOR TREATMENT OF PATIENTS WITH TGCT, A RARE, DEBILITATING, NON-MALIGNANT TUMOR.DAIICHI SANKYO CO LTD - FDA IS EXPECTED TO MAKE A DECISION ON APPROVAL OF PEXIDARTINIB BY AUGUST 3, 2019..  Full Article

Daiichi Sankyo Co Ltd - President And COO Sunao Manabe To Replace George Nakayama As CEO Effective June 17
Friday, 29 Mar 2019 

Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - PRESIDENT AND COO SUNAO MANABE TO REPLACE GEORGE NAKAYAMA AS CEO EFFECTIVE JUNE 17.DAIICHI SANKYO CO LTD - NAKAYAMA TO REMAIN CHAIRMAN AND REPRESENTATIVE DIRECTOR.  Full Article

Astrazeneca And Daiichi Sankyo Enter Collaboration For Novel HER2-Targeting Antibody-Drug Conjugate
Friday, 29 Mar 2019 

March 28 (Reuters) - AstraZeneca Plc ::ASTRAZENECA AND DAIICHI SANKYO ENTER COLLABORATION FOR NOVEL HER2-TARGETING ANTIBODY-DRUG CONJUGATE.ASTRAZENECA - TRANSACTION TO BE FUNDED FROM PROCEEDS OF NEW EQUITY PLACEMENT OF ABOUT $3.5BN.  Full Article

Daiichi Sankyo, AstraZeneca Announce Global Development, Commercialization Collaboration For Trastuzumab Deruxtecan (Ds-8201)
Friday, 29 Mar 2019 

March 29 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO AND ASTRAZENECA ANNOUNCE GLOBAL DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR DAIICHI SANKYO'S HER2 TARGETING ANTIBODY DRUG CONJUGATE FAM- TRASTUZUMAB DERUXTECAN (DS-8201).ASTRAZENECA TO PAY DAIICHI SANKYO UP TO $6.90 BILLION IN TOTAL CONSIDERATION.DAIICHI SANKYO -CO AND ASTRAZENECA TO SHARE EQUALLY DEVELOPMENT AND COMMERCIALIZATION COSTS,PROFITS WORLDWIDE FROM FAM- TRASTUZUMAB DERUXTECAN.ASTRAZENECA'S TOTAL PAYMENT TO DAIICHI SANKYO INCLUDES UPFRONT PAYMENT OF $1.35 BILLION.DAIICHI SANKYO - CO, ASTRAZENECA TO JOINTLY DEVELOP, COMMERCIALIZE TRASTUZUMAB DERUXTECAN AS MONOTHERAPY, COMBINATION THERAPY WORLDWIDE, EXCEPT JAPAN.DAIICHI SANKYO WILL BE SOLELY RESPONSIBLE FOR MANUFACTURING AND SUPPLY OF FAM- TRASTUZUMAB DERUXTECAN.IMPACT ON DAIICHI SANKYO'S CONSOLIDATED RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2019 IS IMMATERIAL.DAIICHI SANKYO - CO, ASTRAZENECA TO SHARE EQUALLY DEVELOPMENT, COMMERCIALIZATION COSTS, PROFITS FROM TRASTUZUMAB DERUXTECAN WORLDWIDE, EXCEPT JAPAN.DAIICHI SANKYO- CO EXPECTED TO BOOK SALES IN U.S., CERTAIN COUNTRIES IN EUROPE, CERTAIN OTHER MARKETS WHERE DAIICHI SANKYO HAS AFFILIATES.ASTRAZENECA IS EXPECTED TO BOOK SALES IN ALL OTHER MARKETS WORLDWIDE, INCLUDING CHINA, AUSTRALIA, CANADA AND RUSSIA.  Full Article

Daiichi Sankyo Confirms Plans To Accelerate BLA Submission To U.S. FDA For Trastuzumab Deruxtecan
Friday, 29 Mar 2019 

March 28 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CONFIRMS PLANS TO ACCELERATE BLA SUBMISSION TO U.S. FDA FOR FAM- TRASTUZUMAB DERUXTECAN (DS-8201) IN HER2 POSITIVE METASTATIC BREAST CANCER POST T-DM1.DAIICHI SANKYO - BLA SUBMISSION FOR FAM- TRASTUZUMAB DERUXTECAN (DS-8201) IN HER2 POSITIVE METASTATIC BREAST CANCER POST T-DM1 ACCELERATED TO 1ST HALF FY 2019.DAIICHI SANKYO - DATA FROM PIVOTAL PHASE 2 DESTINY-BREAST01 STUDY TO FORM BASIS OF BLA SUBMISSION.  Full Article

Daiichi Sankyo Co Ltd Says Ken Keller Appointed President & CEO Of Daiichi Sankyo, Inc., A U.S. Affiliate
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - KEN KELLER APPOINTED PRESIDENT & CEO OF DAIICHI SANKYO, INC., A U.S. AFFILIATE.DAIICHI SANKYO CO LTD - JUNICHI KOGA TO BECOME NEW GLOBAL HEAD OF RESEARCH & DEVELOPMENT UNIT.  Full Article

Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For Minnebro Tablets In Japan
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Exelixis Inc ::EXELIXIS’ COLLABORATOR DAIICHI SANKYO RECEIVES REGULATORY APPROVAL FOR MINNEBRO™ (ESAXERENONE) TABLETS FOR THE TREATMENT OF HYPERTENSION IN JAPAN.EXELIXIS INC - APPROVAL ALLOWS FOR MARKETING OF MINNEBRO FOR THE INDICATION WITHIN JAPAN..  Full Article

Daiichi Sankyo Co Ltd, Anheart Therapeutics Entered Into Worldwide Exclusive License Agreement For DS-6051
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO CO LTD - CO AND ANHEART THERAPEUTICS ENTERED INTO WORLDWIDE EXCLUSIVE LICENSE AGREEMENT FOR DS-6051.DAIICHI SANKYO CO LTD - FINANCIAL TERMS OF AGREEMENT ARE NOT DISCLOSED.  Full Article

Daiichi Sankyo: Announces Reorganization Scheme For Kitasato Daiichi Sankyo Vaccine
Friday, 30 Nov 2018 

Nov 30 (Reuters) - Japan's Daiichi Sankyo Co Ltd <4568.T>::ANNOUNCES REORGANIZATION SCHEME FOR KITASATO DAIICHI SANKYO VACCINE.  Full Article

Daiichi Sankyo Co, Roche To Collaborate On New HER2 Low Companion Diagnostic Test
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO AND ROCHE TO COLLABORATE ON NEW HER2 LOW COMPANION DIAGNOSTIC TEST.DAIICHI SANKYO- UNDER AGREEMENT, ROCHE WILL SEEK TO DEVELOP, MANUFACTURE & COMMERCIALIZE WORLDWIDE AN IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTIC TEST.DAIICHI SANKYO CO - SPECIFIC FINANCIAL TERMS OF AGREEMENT HAVE NOT BEEN DISCLOSED.  Full Article

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

TOKYO Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.